Updated:
Biocon Limited
Biocon was founded in 1978 by Kiran Mazumdar-Shaw, who started the company in her garage with a seed capital of Rs. 10,000 (per company history).
Biocon Limited
Biocon was founded in 1978 by Kiran Mazumdar-Shaw, who started the company in her garage with a seed capital of Rs. 10,000 (per company history). It is a publicly traded pharmaceutical firm headquartered in Bangalore, India. The wealth is not from a single-family fortune but from public shareholding and institutional ownership. Biocon operates through four business segments: generics (including complex APIs and formulations), biosimilars (via its subsidiary Biocon Biologics), novel biologics, and research services (via its subsidiary Syngene). The company's key therapeutic areas are diabetes, cancer, and autoimmune diseases. Confirmed geographies include the US, Europe (UK, Germany, Netherlands, Italy), China, and Brazil. As of FY26, Biocon reported total income of Rs 17,270 crore (approx. $2.1B) and EBITDA of Rs 3,798 crore (per company press release, May 2026). The company employs over 13,000 people and operates manufacturing facilities in India and Malaysia. In April 2026, the US FDA completed a pre-license inspection at Biocon's biosimilars facility in Bengaluru (per company press release, April 2026). Adjacent structures include the Biocon Foundation, a philanthropic arm focused on health and education. Biocon's structural differentiator is its vertical integration from drug discovery through commercial manufacturing, combined with an affordable-innovation mission that targets price-sensitive global markets. This model — rare among Western peers — allows it to deliver biosimilars at 15–30% of the originator's price, fundamentally reshaping access in developing economies.
General information
Firm type
other
Year founded
1978
AUM
Undisclosed
Location
Region
Asia
Country
India
City
Bangalore
Corporate office
Bangalore, India
Principals
Kiran Mazumdar-Shaw
Executive Chairperson
Sector focus
Frequently asked questions
Who leads Biocon's strategic and investment decisions?
Kiran Mazumdar-Shaw serves as Executive Chairperson and is the founder. The Board of Directors includes independent and executive members. The Key Management Team and Executive Committee drive operational decisions across the generics, biosimilars, and research services businesses.
How is Biocon structured between its operating businesses and its R&D arm?
Biocon operates through three primary businesses: Generics (complex APIs and formulations), Biosimilars (via Biocon Biologics), and Research Services (via Syngene, which is a separately listed company). Novel Biologics is an early-stage pipeline within Biocon.
Does Biocon rely on partnerships for commercializing its products globally?
Yes. In select markets like China, Biocon has licensed products to China Medical System (CMS). In Brazil it pursues a B2B partnering model. In the US and parts of Europe (UK, Germany, Netherlands, Italy) it maintains a direct commercial presence.
What is Biocon's approach to pricing and access?
Biocon's strategy centers on affordability through vertical integration, scale, and efficiency. The company aims to deliver biosimilars at 15–30% of the originator's price, particularly targeting underserved populations in developing countries.
What is Biocon's relationship with the Biocon Foundation?
The Biocon Foundation is Biocon's philanthropic arm focused on health, education, and social development in India. It is funded by Biocon and partners with government agencies, NGOs, and academic institutions.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: